Your browser doesn't support javascript.
loading
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
Giovannoni, Gavin; Singer, Barry A; Issard, Delphine; Jack, Dominic; Vermersch, Patrick.
Afiliación
  • Giovannoni G; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Singer BA; The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, USA.
  • Issard D; Department of Biostatistics, Cytel Inc., Geneva, Switzerland.
  • Jack D; Global Medical Affairs, Neurology and Immunology, Merck Serono Ltd, Feltham, UK (an affiliate of Merck KGaA).
  • Vermersch P; Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.
Mult Scler ; 28(8): 1219-1228, 2022 07.
Article en En | MEDLINE | ID: mdl-34634968
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2022 Tipo del documento: Article